PERKHIDMATAN INI TIDAK TERSEDIA DI RANTAU ANDA

ABT

Kanada

Diasas

2018 (8 Tahun)

Diasaskan

Terakhir dalam talian: Tiada aktiviti terkini

Tuntut syarikat Lawati Laman Web

TrustScore tidak tersediaSkor tidak mencukupi untuk memaparkan trend.

Jadilah yang pertama menilai dan mengulas syarikat ini.

SKOR KESELURUHAN

Lesen

--/40

Ulasan

--/60

0 ulasan

Disediakan oleh TrustFinance

TrustScore tidak tersediaSkor tidak mencukupi untuk memaparkan trend.

Jadilah yang pertama menilai dan mengulas syarikat ini.

TrustFinance bukan penasihat kewangan berlesen dan tidak bergabung dengan mana-mana institusi kewangan di rantau anda. Kami menggalakkan anda menjalankan kajian sendiri sebelum membuat sebarang keputusan pelaburan.

FTD LIMITED

(505 ulasan)

British Virgin Islands

2017

(9 tahun)

Maklumat Keselamatan :

BVI FSC

Maklumat Keselamatan

Amaran

Syarikat ini pada masa ini Tidak Terbukti.

Sila berwaspada terhadap risiko yang berpotensi!

Lesen

Lesen Gred A

Dikeluarkan oleh pengawal selia yang terkenal di peringkat global, lesen ini memastikan perlindungan pedagang tertinggi melalui pematuhan ketat, pengasingan dana, insurans, dan audit berkala. Penyelesaian pertikaian dan pematuhan kepada piawaian AML/CTF seterusnya meningkatkan keselamatan.

Lesen Gred B

Diberikan oleh pengawal selia serantau yang dihormati, lesen ini menawarkan langkah keselamatan yang mantap seperti pengasingan dana, pelaporan kewangan, dan skim pampasan. Walaupun kurang ketat sedikit berbanding Tahap 1, ia menyediakan perlindungan serantau yang boleh dipercayai.

Lesen Gred C

Dikeluarkan oleh pengawal selia di pasaran baru muncul, lesen ini menawarkan perlindungan asas seperti keperluan modal minimum dan dasar AML. Pengawasan kurang ketat, jadi pedagang harus berhati-hati dan mengesahkan langkah keselamatan.

Lesen Gred D

Daripada bidang kuasa dengan pengawasan minimum, lesen ini seringkali kekurangan perlindungan utama seperti pengasingan dana dan insurans. Walaupun menarik untuk fleksibiliti operasi, ia menimbulkan risiko yang lebih tinggi kepada pedagang.

Maklumat Syarikat

Kenali ABT

Maklumat Syarikat

Kenali ABT

ABT GROUP LTD, operating under the brand name ABT, is a financial services provider that offers online trading through the MetaTrader 5 (MT5) platform. The company provides access to leveraged trading on a variety of asset classes, including foreign exchange, global indices, precious metals, energies, and cryptocurrencies. Registered in the offshore jurisdiction of St. Vincent and the Grenadines, the firm targets a global retail trading audience.

Tunjukkan Lagi

Industri

Forex Broker RuncitUTAMA
Kripto Mata wang kripto
Kewangan Nasihat Kewangan

Perisian

Tiada data tersedia

Nampaknya bahagian ini kosong. Kembali semula untuk kemas kini!

Hubungi

Sosial

Ulasan

ABT Ulasan

Ulasan

Jumlah 0

Susun

Penapis

PERKHIDMATAN INI TIDAK TERSEDIA DI RANTAU ANDA

ABT

Kanada

Diasas

2018 (8 Tahun)

Diasaskan

Terakhir dalam talian: Tiada aktiviti terkini

Tuntut syarikat Lawati Laman Web

TrustScore tidak tersediaSkor tidak mencukupi untuk memaparkan trend.

Jadilah yang pertama menilai dan mengulas syarikat ini.

SKOR KESELURUHAN

Lesen

--/40

Ulasan

--/60

0 ulasan

Disediakan oleh TrustFinance

TrustScore tidak tersediaSkor tidak mencukupi untuk memaparkan trend.

Jadilah yang pertama menilai dan mengulas syarikat ini.

FTD LIMITED

(505 ulasan)

British Virgin Islands

2017

(9 tahun)

Maklumat Keselamatan :

BVI FSC

Maklumat Keselamatan

Amaran

Syarikat ini pada masa ini Tidak Terbukti.

Sila berwaspada terhadap risiko yang berpotensi!

Lesen

Lesen Gred A

Lesen Gred B

Lesen Gred C

Lesen Gred D

Maklumat Syarikat

Kenali ABT

Maklumat Syarikat

Kenali ABT

Tunjukkan Lagi

Industri

Forex Broker RuncitUTAMA
Kripto Mata wang kripto
Kewangan Nasihat Kewangan

Perisian

Tiada data tersedia

Nampaknya bahagian ini kosong. Kembali semula untuk kemas kini!

Hubungi

Sosial

Pengguna yang melihat ABT juga melihat…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

Berita

TrustFinance Agensi Perisikan

Tarikh penyelidikan: Jul 28, 2026

Abbott Laboratories (NYSE: ABT) is highlighted as a strong investment opportunity, with an average target price of $118.64 suggesting a potential upside of 40.7% from its current price of $84.32. The company, with a market cap of $146.87 billion, has a diversified portfolio in pharmaceuticals, diagnostics, nutritionals, and medical devices. Despite recent price dips, its long-term outlook remains positive, supported by solid revenue growth of 7.80% and a return on equity of 12.33%. Analysts are bullish, giving 21 buy ratings and no sell ratings, indicating a consensus target price range between $92.00 and $143.00. The stock's current trading position suggests a buying opportunity for long-term investors, with strong fundamentals and a decent dividend yield of 2.99%. Abbott's innovative healthcare solutions position it well for future growth.

Abbott Laboratories (NYSE: ABT) is highlighted as a strong investment opportunity, with an average target price of $118.64 suggesting a potential upside of 40.7% from its current price of $84.32. The company, with a market cap of $146.87 billion, has a diversified portfolio in pharmaceuticals, diagnostics, nutritionals, and medical devices. Despite recent price dips, its long-term outlook remains positive, supported by solid revenue growth of 7.80% and a return on equity of 12.33%. Analysts are bullish, giving 21 buy ratings and no sell ratings, indicating a consensus target price range between $92.00 and $143.00. The stock's current trading position suggests a buying opportunity for long-term investors, with strong fundamentals and a decent dividend yield of 2.99%. Abbott's innovative healthcare solutions position it well for future growth.

Barclays analysts predict a significant bull run in the medical technology industry, highlighting Abbott Laboratories (NYSE: ABT) as a key beneficiary. They expect a resurgence due to postponed medical procedures from last year and an aging population. Abbott has shown strong earnings growth of 217% year-over-year and a revenue increase of over 35%. Analysts set a price target of $150.00 for ABT, indicating a potential upside of nearly 30%. Investors are advised to consider buying ABT stock ahead of the anticipated market recovery.

Barclays analysts predict a significant bull run in the medical technology industry, highlighting Abbott Laboratories (NYSE: ABT) as a key beneficiary. They expect a resurgence due to postponed medical procedures from last year and an aging population. Abbott has shown strong earnings growth of 217% year-over-year and a revenue increase of over 35%. Analysts set a price target of $150.00 for ABT, indicating a potential upside of nearly 30%. Investors are advised to consider buying ABT stock ahead of the anticipated market recovery.

The website provides a comprehensive suite of research tools and resources for investors, including stock screeners, financial calculators, news feeds, and premium reports. It features various stock categories, trending stocks, analyst ratings, and corporate events. The content also includes detailed information about Abbott Laboratories, including stock analysis, market performance, and corporate overview, emphasizing its role in healthcare and diagnostics. Additional features include dividend information, earnings announcements, and insider trading data.

The website provides a comprehensive suite of research tools and resources for investors, including stock screeners, financial calculators, news feeds, and premium reports. It features various stock categories, trending stocks, analyst ratings, and corporate events. The content also includes detailed information about Abbott Laboratories, including stock analysis, market performance, and corporate overview, emphasizing its role in healthcare and diagnostics. Additional features include dividend information, earnings announcements, and insider trading data.

Disediakan oleh Analisis AI TrustFinance

Ulasan

ABT Ulasan

Ulasan

Jumlah 0

Analisis Ulasan AI

Mari biarkan TrustFinance AI meringkaskan semua ulasan untuk anda.

Disediakan oleh Analisis AI TrustFinance

Susun

Penapis